Equities

EBOS Group Ltd

EBOS Group Ltd

Actions
Health CareMedical Equipment and Services
  • Price (NZD)40.49
  • Today's Change0.04 / 0.10%
  • Shares traded19.78k
  • 1 Year change+25.01%
  • Beta0.4241
Data delayed at least 20 minutes, as of Jun 28 2022 01:55 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Ebos Group Limited is a marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. The Company is also an animal care products marketer and distributor. Its segments include Healthcare, Animal care and Corporate. The Healthcare segment incorporates the sale of healthcare products in a range of sectors, own brands, retail healthcare, wholesale activities and logistics. The Animal care segment incorporates the sale of animal care products in a range of sectors, own brands, retail and wholesale activities. Its businesses include Community Pharmacy, Institutional Healthcare, Contract Logistics and Animal Care. Community Pharmacy includes Symbion, Endeavour Consumer Health, ProPharma, DoseAid and Intellipharm. Institutional Healthcare includes EBOS Healthcare, Onelink, Clinect and Zest. Contract Logistics comprises Healthcare Logistics, Symbion Contract Logistics and Symbion Clinical Trials. Animal Care includes Masterpet, Lyppard, Animates and Vitapet.

  • Revenue in NZD (TTM)10.76bn
  • Net income in NZD213.34m
  • Incorporated1922
  • Employees3.30k
  • Location
    EBOS Group Ltd108 Wrights RoadCHRISTCHURCH 8024New ZealandNZL
  • Phone+64 33380999
  • Fax+64 33395090
  • Websitehttp://www.ebosgroup.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
EBO:NZC since
announced
Transaction
value
Pioneer Medical LtdDeal completed18 Aug 202118 Aug 2021Deal completed28.95%--
Sentry Medical Pty LtdDeal completed18 Aug 202118 Aug 2021Deal completed28.95%57.99m
Data delayed at least 20 minutes, as of Jun 28 2022 01:55 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SUZUKEN CO., LTD.26.15bn168.57m4.63bn15.04k23.380.805316.450.177163.57163.5725,313.924,749.591.9815.314.44--1.281.753.264.597.218.210.64820.92391.07--0.0029.464.910.975482.31-7.552.145.92
TAISHO PHARMACEUTICAL HOLDINGS Co Ltd3.14bn153.68m5.28bn9.20k33.070.580811.871.68160.26160.263,289.399,125.470.30392.295.14--1.693.221.873.5661.0963.265.579.775.36----33.51-4.89-0.8411-1.46-14.5410.26-1.89
Shandong Buchang Pharmaceuticals Co Ltd3.69bn310.80m5.33bn8.35k16.631.47--1.441.191.1914.1213.430.66561.2412.451,869,074.005.358.217.5811.7271.9579.518.0311.680.730611.160.189969.67-1.525.05-30.72-6.13-8.55-17.73
Jointown Pharmaceutical Group Co Ltd29.57bn501.22m5.37bn29.34k10.821.04--0.18161.121.1263.6512.721.467.603.844,258,261.002.693.198.679.837.618.531.842.151.0251.750.582841.3510.4214.74-17.7624.343.80--
China Medicine Health Industry Co Ltd8.56bn160.96m5.54bn8.72k24.601.59--0.64740.63650.636533.869.831.114.962.954,151,740.002.295.004.9111.5513.8816.442.063.931.286.520.323137.30-7.836.91-50.63-7.3912.03-7.36
China Medical System Holdings1.97bn713.32m6.17bn5.29k8.712.058.053.131.431.433.966.080.58494.906.821,846,330.0021.2219.2823.8721.8374.9372.5736.2934.393.32--0.126840.0720.0311.2119.2517.0123.2316.47
Aurobindo Pharma Ltd4.75bn535.78m6.24bn19.36k11.651.268.181.3245.1945.19400.27419.430.69221.226.24--7.8111.5310.8118.3056.7754.8011.2914.541.30328.320.1047.88-5.329.22-50.362.849.8129.20
China Resources Pharmaceutical Group Ltd47.77bn760.25m6.82bn65.00k8.970.6633.570.14270.59990.599937.698.111.037.423.793,643,172.002.903.4011.4212.0314.9416.432.813.141.046.690.373221.8718.158.6114.315.9610.5810.76
EBOS Group Ltd10.76bn213.34m7.52bn3.30k30.713.1925.540.69841.291.2965.2012.422.2910.698.25--4.504.548.238.7810.9310.741.971.910.916516.110.20274.464.997.1514.029.7238.468.96
Kobayashi Pharmaceutical Co Ltd1.85bn229.09m8.02bn3.45k33.293.3527.974.35250.80250.802,022.512,489.230.66183.793.8845,676,320.008.218.0210.0410.3956.8658.8112.4111.663.39--0.003230.443.15--2.66------
Data as of Jun 28 2022. Currency figures normalised to EBOS Group Ltd's reporting currency: New Zealand Dollar NZD

Institutional shareholders

14.73%Per cent of shares held by top holders
HolderShares% Held
Harbour Asset Management Ltd.as of 01 Sep 20215.32m2.81%
Accident Compensation Corp.as of 16 Jul 20214.91m2.59%
Fidelity Management & Research Co. LLCas of 08 Dec 20204.19m2.21%
Norges Bank Investment Managementas of 31 Dec 20212.88m1.52%
Guardians of New Zealand Superannuationas of 30 Jun 20212.78m1.47%
The Vanguard Group, Inc.as of 02 Jun 20222.60m1.37%
FMR Investment Management (UK) Ltd.as of 08 Dec 20202.41m1.27%
Capital Research & Management Co. (Global Investors)as of 31 Mar 20221.02m0.54%
Fidelity Management & Research (Japan) Ltd.as of 08 Dec 2020917.01k0.48%
Dimensional Fund Advisors LPas of 02 Jun 2022867.24k0.46%
More ▼
Data from 30 Jun 2021 - 22 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.